Laboratory Monitoring of Anticoagulant Medications: Focus on Novel Oral Anticoagulants

References

• . Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2012. http://www.xareltohcp.com/sites/default/files/shared/xarelto_0.pdf#zoom=100. Accessed April 23, 2012
   Google Scholar
• . Eliquis [package insert]. Uxbridge, UK: Bristol-Myers Squibb/Pfizer EEIG; 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. Accessed October 25, 2011
   Google Scholar
• . Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2012. http://bidocs.boehringer-ingelheim.com/BIWebAc-cess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed February 7, 2012
   Google Scholar
• . Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873–880
   PubMed Web of Science ®Google Scholar
• . Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292–303
   PubMed Web of Science ®Google Scholar
• . Ogata K, Mendell-Harary J, Tachibana M, . Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743–753
   PubMed Web of Science ®Google Scholar
• . Raghavan N, Frost CE, Yu Z, . Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74–81
   PubMed Web of Science ®Google Scholar
• . Marlar RA, Gausman JN. Do you report an accurate international normalized ratio? Find out using local verification and calibration. Lab Medicine. 2011;42(3):176–181
   Google Scholar
• . Marlar RA, Cook J, Johnston M, . One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test; Approved Guideline. 2nd ed. CLSI document H47-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2008
   Google Scholar
• . Poller L. International Normalized Ratios (INR): the first 20 years. J Thromb Haemost. 2004;2(6):849–860
   PubMedGoogle Scholar
• . Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133( 6 suppl):160S–198S
   PubMed Web of Science ®Google Scholar
• . Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141( 2 suppl):e44S–e88S
   PubMed Web of Science ®Google Scholar
• . Poller L, Ibrahim S, Keown M, Pattison A, Jespersen J. The prothrombin time/international normalized ratio (PT/INR) line: derivation of local INR with commercial thromboplastins and coagulometers—two independent studies. J Thromb Haemost. 2011;9(1):140–148
   PubMedGoogle Scholar
• . Fairweather RB, Ansell J, van den Besselaar AM, . College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy. Arch Pathol Lab Med. 1998;122(9):768–781
   PubMedGoogle Scholar
• . Olson JD, Arkin CF, Brandt JT, . College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998;122(9):782–798
   PubMed Web of Science ®Google Scholar
• . Dudek MM, Kent N, Gustafsson KM, Lindahl TL, Killard AJ. Fluorescence-based blood coagulation assay device for measuring activated partial thromboplastin time. Anal Chem. 2011;83(1):319–328
   PubMedGoogle Scholar
• . Dudek MM, Harris LF, Killard AJ. Evaluation of activated partial thromboplastin time (aPTT) reagents for application in biomedical diagnostic device development. Int J Lab Hematol. 2011;33(3):272–280
   PubMedGoogle Scholar
• . Perry D, Todd T. Apractical guide to laboratory haemostasis: activated clotting time (ACT). 2011. http://www.practical-haemostasis.com/Miscellaneous/Miscellaneous%20Tests/act.html. Accessed February 12, 2013
   Google Scholar
• . Kostousov V. Activated clotting time. 2011.http://emedicine.medscape.com/article/2084818-overview#a30. Accessed February 12, 2013
   Google Scholar
• . de Denus S, Spinler SA. Clinical monitoring of direct thrombin inhibitors using the ecarin clotting time. Pharmacotherapy. 2002;22(4):433–435
   PubMedGoogle Scholar
• . Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb. 2003;33(4):173–183
   PubMed Web of Science ®Google Scholar
• . Choi TS, Khan AI, Greilich PE, Kroll MH. Modified plasma-based ecarin clotting time assay for monitoring of recombinant hirudin during cardiac surgery. Am J Clin Pathol. 2006;125(2):290–295
   PubMedGoogle Scholar
• . Perry D, Todd T. A practical guide to laboratory haemostasis: ecarin clotting time. 2011. http://www.practical-haemostasis.com/Miscellaneous/Miscellaneous%20Tests/ecarin_ct.html. Accessed February 12, 2013
   Google Scholar
• . Lange U, Nowak G, Bucha E. Ecarin chromogenic assay—a new method for quantitative determination of direct thrombin inhibitors like hirudin. Pathophysiol Haemost Thromb. 2003;33(4):184–191
   PubMed Web of Science ®Google Scholar
• . Siegmund R, Boer K, Poeschel K, Wolf G, Deufel T, Kiehntopf M. Comparison of the ecarin chromogenic assay and different aPTT assays for the measurement of argatroban concentrations in plasma from healthy individuals and from coagulation factor deficient patients. Thromb Res. 2008;123(1):159–165
   PubMed Web of Science ®Google Scholar
• . Guy S, Kitchen S, Laidlaw S, Cooper P, Woolley A, Maclean R. The use of ecarin chromogenic assay and prothrombinase induced clotting time in the monitoring of lepirudin for the treatment of heparin-induced thrombocytopenia. Br J Haematol. 2008;142(3):466–468
   PubMedGoogle Scholar
• . Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012;107(5):985–997
   PubMed Web of Science ®Google Scholar
• . Crookston K, Rosenbaum L, Gober-Wilcox J. PathologyOutlines.com. Coagulation. 2011. http://www.pathologyoutlines.com/coagulation.html#thrombintime. Accessed February 12, 2013
   Google Scholar
• . Flanders MM, Crist R, Rodgers GM. Comparison of five thrombin time reagents. Clin Chem. 2003;49(1):169–172
   PubMedGoogle Scholar
• . Robert S, Mullier F, Mekouar H, . Comparison of laboratory assays to measure rivaroxaban and dabigatran. Blood (ASH Annual Meeting Abstracts). 2010;116(21):3332
   Google Scholar
• . Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23(2):138–143
   PubMed Web of Science ®Google Scholar
• . Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost. 2007;98(1):234–242
   PubMedGoogle Scholar
• . Avecilla ST, Ferrell C, Chandler WL, Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol. 2012;137(4):572–574
   PubMed Web of Science ®Google Scholar
• . Perry D, Todd T. A practical guide to laboratory haemostasis: anti-Xa assays. 2011. http://www.practical-haemostasis.com/Miscellaneous/Miscellaneous%20Tests/anti_xa_assays.html. Accessed February 12, 2013
   Google Scholar
• . Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med. 1998;122(9):799–807
   PubMed Web of Science ®Google Scholar
• . Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS. Activated partial thromboplastin time versus anti-factor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother. 2011;45(7–8):861–868
   PubMed Web of Science ®Google Scholar
• . Gehrie E, Laposata M. Test of the month: the chromogenic antifactor Xa assay [published online ahead of print October 14, 2011]. Am J Hematol
   Google Scholar
• . Ignjatovic V, Summerhayes R, Gan A, . Monitoring unfractionated heparin (UFH) therapy: which anti-factor Xa assay is appropriate? Thromb Res. 2007;120(3):347–351
   PubMedGoogle Scholar
• . Yin ET, Rozin T. Heptest®-POC-Hi, a new simple one-step point of care (POC) anti-Xa clotting assay for monitoring heparin activity during cardiac surgery. J Thromb Haemost. 2005;3( suppl 1):Abstract P1882
   Google Scholar
• . Abildgaard U, Norrheim L, Larsen AE, Nesvold A, Sandset PM, Odegaard OR. Monitoring therapy with LMW heparin: a comparison of three chromogenic substrate assays and the Heptest clotting assay. Haemostasis. 1990;20(4):193–203
   PubMedGoogle Scholar
• . Samama MM, Martinoli JL, LeFlem L, . Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor. Thromb Haemost. 2010;103(4):815–825
   PubMed Web of Science ®Google Scholar
• . Samama MM, Contant G, Spiro TE, . Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012;107(2):379–387
   PubMed Web of Science ®Google Scholar
• . Harenberg J, Kramer R, Giese C, Marx S, Weiss C, Wehling M. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis. 2011;32(3):267–271
   PubMed Web of Science ®Google Scholar
• . Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104(6):1263–1271
   PubMed Web of Science ®Google Scholar
• . Korte W, Jovic R, Hollenstein M, Degiacomi P, Gautschi M, Ferrandez A. The uncalibrated prothrombinase-induced clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin. Hämostaseologie. 2010;30(4):212–216
   PubMed Web of Science ®Google Scholar
• . Calatzis A, Peetz D, Haas S, Spannagl M, Rudin K, Wilmer M. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Am J Clin Pathol. 2008;130(3):446–454
   PubMedGoogle Scholar
• . Harenberg J, Giese C, Hagedorn A, Traeger I, Fenyvesi T. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time. Semin Thromb Hemost. 2007;33(05):503–507
   PubMedGoogle Scholar
• . Perry D, Todd T. A practical guide to laboratory haemostasis: dilute Russell's viper venom time. 2011. http://www.practical-haemostasis.com/Thrombophilia%20Tests/APS/drvvt.html. Accessed April 10. 2012
   Google Scholar
• . Harder S, Parisius J, Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by prothrombinase-induced clotting time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res. 2008;123(2):396–403
   PubMedGoogle Scholar
• . Hillarp A, Baghaei F, Fagerberg Blixter I, . Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2010;9(1):133–139
   Google Scholar
• . Graff J, Picard-Willems B, Harder S. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a. Int J Clin Pharmacol Ther. 2007;45(4):237–243
   PubMedGoogle Scholar
• . Raivio P, Kuitunen A, Petaja J, Ilveskero S, Lassila R. Monitoring high-dose heparinization during cardiopulmonary by-pass—a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays. Thromb Haemost. 2008;99(2):427–434
   PubMedGoogle Scholar
• . Lindahl TL, Baghaei F, Blixter IF, . Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105(2):371–378
   PubMed Web of Science ®Google Scholar
• . Baruch L, Sherman O. Potential inaccuracy of point-of-care INR in dabigatran-treated patients. Thromb Pharmacother. 2011;45(7–8):e40
   Google Scholar
• . van Ryn J, Stangier J, Haertter S, . Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–1127
   PubMed Web of Science ®Google Scholar
• . van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med. 2012;125(4):417–420
   PubMedGoogle Scholar
• . Liesenfeld KH, Lehr T, Dansirikul C, . Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168–2175
   PubMed Web of Science ®Google Scholar
• . Ezekowitz MD, Reilly PA, Nehmiz G, . Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100(9):1419–1426
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. FDA Advisory Committee Briefing Document. Dabigatran. 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM247244.pdf. Accessed December 4, 2012
   Google Scholar
• . Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. Thromb Haemost. 2012;107(5):838–847
   PubMed Web of Science ®Google Scholar
• . Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost. 2010;104(5):1078–1079
   PubMedGoogle Scholar
• . Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50(10):675–686
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. Johnson and Johnson Pharmaceutical Research and Development. Advisory committee briefing document: rivaroxaban for the prevention of stroke and non-central nervous system (CNS) systemic embolism in patients with atrial fibrillation. 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM270797.pdf. Accessed December 4, 2012
   Google Scholar
• . Harenberg J, Marx S, Krämer R, Giese C, Weiss C. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinolysis. 2011;22(8):637–641
   PubMedGoogle Scholar
• . US Food and Drug Administration. FDA draft briefing document for the cardiovascular and renal drugs committee (CRDAC). 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm270796.pdf. Accessed April 17, 2012
   Google Scholar
• . Zhao X, Sun P, Zhou Y, . Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br J Clin Pharmacol. 2009;68(1):77–88
   PubMedGoogle Scholar
• . Graff J, von Hentig N, Misselwitz F, . Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol. 2007;47(11):1398–1407
   PubMedGoogle Scholar
• . Merriman E, Kaplan Z, Butler J, Malan E, Gan E, Tran H. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost. 2011;105(2):385–386
   PubMedGoogle Scholar
• . Barrett YC, Wang Z, Knabb RM. A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors [published online ahead of print April 2, 2012]. Clin Appl Thromb Hemost
   Google Scholar
• . Barrett YC, Wang J, Song Y, . A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thromb Haemost. 2012;107(5):916–924
   PubMed Web of Science ®Google Scholar
• . He K, Luettgen JM, Zhang D, . Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet. 2011;36(3):129–139
   PubMed Web of Science ®Google Scholar
• . Becker RC, Yang H, Barrett Y, . Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis. 2011;32(2):183–187
   PubMed Web of Science ®Google Scholar
• . Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res. 2012;129(4):e77–e82
   PubMed Web of Science ®Google Scholar